It argues the more useful question is whether the medication fits an individual health profile, and says the provider should assess kidney and pancreatic function, medication interactions, pregnancy status and personal history before deciding
There is currently no FDA-approved indication for tirzepatide specifically for Hashimoto's disease, and no large-scale randomized controlled trials have evaluated tirzepatide as a treatment for this autoimmune thyroid condition
Three things matter when comparing these numbers
Eli Lilly believes orforglipron will show a comparable effect, though the data remains blinded
So in patients for whom this matters, who may have heart disease, kidney disease, or obesity complications, then the benefits of GLP-1s do outweigh the potential risks, which are typically gastrointestinal side effects
Turnaround times typically range from 5 to 10 business days